Ibrutinib (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ibrutinib" in French language version.

refsWebsite

Global rank French rank

2,374^th place

298^th place

1,293^rd place

405^th place

1hematologylibrary.org

low place

low place

low place

7,741^st place

2,393^rd place

506^th place

ascopubs.org

jco.ascopubs.org

Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies, J Clin Oncol, 2013;31:88-94

hematologylibrary.org

bloodjournal.hematologylibrary.org

Herman SE, Gordon AL, Hertlein E et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765, Blood, 2011;117:6287-6296

nejm.org

Woyach JA, Furman RR, Liu TM et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor Ibrutinib, N Engl J Med, 2014;370:2286-2294
Dimopoulos MA, Tedeschi A, Trotman J et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia, N Engl J Med, 2018;378:2399-2410
Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N Engl J Med, 2013;369:32-42
Burger JA, Tedeschi A, Barr PM et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia, N Engl J Med, 2015;373:2425-2437
Jain N, Keating M, Thompson P et al. Ibrutinib and venetoclax for first-line treatment of CLL, N Engl J Med, 2019;380:2095-2103

pnas.org

Honigberg LA, Smith AM, Sirisawad M et al. (http://www.pnas.org/content/107/29/13075 The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy], Proc Natl Acad Sci U S A, 2010;107:13075-13080

thelancet.com

Dreyling M, Jurczak W, Jerkeman M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study, Lancet, 2016;387:770–778